The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cytochrome P450-mediated metabolism in the human gut wall
Open accessAbstract
Objective: Although the human small intestine serves primarily as an absorptive organ for nutrients and water, it also has the ability to metabolise drugs. Interest in the small intestine as a drug-metabolising organ has been increasing since the realisation that it is probably the most important extrahepatic site of drug biotransformation. Key findings: Among the metabolising enzymes present in the small intestinal mucosa, the cytochromes P450 (CYPs) are of particular importance, being responsible for the majority of phase I drug metabolism reactions. Many drug interactions involving induction or inhibition of CYP enzymes, in particular CYP3A, have been proposed to occur substantially at the level of the intestine rather than exclusively within the liver, as originally thought. CYP3A and CYP2C represent the major intestinal CYPs, accounting for approximately 80% and 18%, respectively, of total immunoquantified CYPs. CYP2J2 is also consistently expressed in the human gut wall. In the case of CYP1A1, large interindividual variation in the expression levels has been reported. Data for the intestinal expression of the polymorphic CYP2D6 are conflicting. Several other CYPs, including the common hepatic isoform CYP2E1, are expressed in the human small intestine to only a very low extent, if at all. The distribution of most CYP enzymes is not uniform along the human gastrointestinal tract, being generally higher in the proximal regions of the small intestine. Summary: This article reviews the current state of knowledge of CYP enzyme expression in human small intestine, the role of the gut wall in CYP-mediated metabolism, and how this metabolism limits the bioavailability of orally administered drugs. Possible interactions between drugs and CYP activity in the small intestine are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 5×
“The second most abundantly expressed CYP subfamily in human liver and along the small intestine is CYP2C.([3,4,97,98,127]) It has been estimated that the CYP2C subfamily accounts for the metabolism of approximately 20% of clinically prescribed drugs.”
BackgroundInfluentialThiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Artursson, P., & Karlsson, J. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91647-u · Cited by 1,893
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 1,754
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,706
P450 GENES: STRUCTURE, EVOLUTION, AND REGULATION
Nebert, D. W., & Gonzalez, F. J. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004501 · Cited by 1,585
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Principles of Anatomy and Physiology
Baker, G. F., Tortora, G. J., & Nostakos, N. P. A. (1976) · The American Journal of Nursing · doi:10.2307/3423898 · Cited by 1,312
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Shimada, T., Hayes, C. L., Yamazaki, H., Amin, S., Hecht, S. S., Guengerich, F. P., & Sutter, T. R. (1996) · PubMed · Cited by 895
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
Paine, M. F., Hart, H. L., Ludington, S. S., Haining, R. L., Rettie, A. E., & Zeldin, D. C. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008672 · Cited by 870
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
Miners, J. O., & Birkett, D. J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00721.x · Cited by 844
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0832-2 · Cited by 795
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Grapefruit juice–drug interactions
Bailey, D. G., Malcolm, J., Arnold, O., & David Spence, J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00764.x · Cited by 740
Lown, K. S., Mayo, R. R., Leichtman, A. B., Hsiao, H.-L., Turgeon, D. K., Schmiedlin-Ren, P., Brown, M. B., Guo, W., Rossi, S. J., Benet, L. Z., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90027-8 · Cited by 680
17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1.
Hayes, C. L., Spink, D. C., Spink, B. C., Cao, J. Q., Walker, N. J., & Sutter, T. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9776 · Cited by 632
Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W., & Watkins, P. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119439 · Cited by 624
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
Goldstein, J. A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01499.x · Cited by 617
Thummel, K. E., O'Shea, D., Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., & Wilkinson, G. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90177-0 · Cited by 617
Interaction of citrus juices with felodipine and nifedipine
Bailey, D., Spence, J., Munoz, C., & Arnold, J. M. O. (1991) · The Lancet · doi:10.1016/0140-6736(91)90872-m · Cited by 596
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584
Chan, L. M. S., Lowes, S., & Hirst, B. H. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.07.003 · Cited by 582
Capdevila, J. H., Falck, J. R., & Harris, R. C. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32049-6 · Cited by 552
Challenges for the oral delivery of macromolecules
Goldberg, M., & Gomez-Orellana, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1067 · Cited by 544
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
de Waziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J. P., & Beaune, P. H. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12474-9 · Cited by 502
Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 494
The intestinal epithelial stem cell: the mucosal governor
POTTEN, C. S., BOOTH, C., & PRITCHARD, D. M. (1997) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.1997.280362.x · Cited by 488
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., & Guzelian, P. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113156 · Cited by 480
Wu, S., Moomaw, C. R., Tomer, K. B., Falck, J. R., & Zeldin, D. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3460 · Cited by 473
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism
Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G., & Thummel, K. E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.162 · Cited by 449
The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications
Meunier, V., Bourri�, M., Berger, Y., & Fabre, G. (1995) · Cell Biology and Toxicology · doi:10.1007/bf00756522 · Cited by 434
First-pass metabolism of cyclosporin by the gut
Kolars, J. C., Watkins, P. B., Merion, R. M., & Awni, W. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)92302-i · Cited by 422
First-pass metabolism of midazolam by the human intestine*
Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9b · Cited by 418
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Noninvasive tests of CYP3A enzymes
Watkins, P. B. (1994) · Pharmacogenetics · doi:10.1097/00008571-199408000-00001 · Cited by 408
(1991) · Choice Reviews Online · doi:10.5860/choice.29-0661 · Cited by 396
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
The barrier function of CYP3A4 and P-glycoprotein in the small bowel
Watkins, P. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00041-0 · Cited by 391
Prediction of Intestinal First-Pass Drug Metabolism
Yang, J., Jamei, M., Yeo, K., Tucker, G., & Rostami-Hodjegan, A. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109733 · Cited by 366
CYP3A gene expression in human gut epithelium
Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., & Watkins, P. B. (1994) · Pharmacogenetics · doi:10.1097/00008571-199410000-00003 · Cited by 365
Interaction between grapefruit juice and midazolam in humans*
Kupferschmidt, H. H. T., Ha, H. R., Ziegler, W. H., Meier, P. J., & Krähenbühl, S. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90068-3 · Cited by 359
Wu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., & Wacher, V. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90168-x · Cited by 356
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
Ingelman-Sundberg, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0819-z · Cited by 353
Is the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
A potentially hazardous interaction between erythromycin and midazolam
Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J.-J., & Neuvonen, P. J. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.25 · Cited by 351
Lown, K. S., Kolars, J. C., Thummel, K. E., Barnett, J. L., Kunze, K. L., Wrighton, S. A., & Watkins, P. B. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08440-5 · Cited by 350
Disposition of intravenous and oral cyclosporine after administration with grapefruit juice*
Ducharme, M. P., Warbasse, L. H., & Edwards, D. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90032-2 · Cited by 347
Characterization of Human Small Intestinal Cytochromes P-450
Zhang, Q.-Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., & Kaminsky, L. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15229-4 · Cited by 343
Bièche, I., Narjoz, C., Asselah, T., Vacher, S., Marcellin, P., Lidereau, R., Beaune, P., & de Waziers, I. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32810f2e58 · Cited by 341
Kivisto, K., Kroemer, H., & Eichelbaum, M. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05796.x · Cited by 340
Hebert, M. F., Roberts, J. P., Prueksaritanont, T., & Benet, L. Z. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.171 · Cited by 337
Pavek, P., & Dvorak, Z. (2008) · Current Drug Metabolism · doi:10.2174/138920008783571774 · Cited by 327
Schmiedlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S., & Watkins, P. B. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.741 · Cited by 325
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction
Thummel, K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00039-2 · Cited by 318
Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA
Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1108 · Cited by 314
Intestinal permeability and its relevance for absorption and elimination
Lennernäs, H. (2007) · Xenobiotica · doi:10.1080/00498250701704819 · Cited by 304
Drug–Grapefruit Juice Interactions
Kane, G. C., & Lipsky, J. J. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.9.933 · Cited by 301
Regulation of intestinal blood flow
Matheson, P. J., Wilson, M. A., & Garrison, R. N. (2000) · Journal of Surgical Research · doi:10.1006/jsre.2000.5862 · Cited by 296
Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
Benet, L. Z., Izumi, T., Zhang, Y., Silverman, J. A., & Wacher, V. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00034-6 · Cited by 292
Hunter, J., & Hirst, B. H. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00497-3 · Cited by 291
Suzuki, H., & Sugiyama, Y. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00178-0 · Cited by 291
Labroo, R. B., Paine, M. F., Thummel, K. E., & Kharasch, E. D. (1997) · PubMed · Cited by 291
Gastrointestinal absorption of drugs: methods and studies
Barthe, L., Woodley, J., & Houin, G. (1999) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1999.tb00334.x · Cited by 290
Regulation and Significance of Apoptosis in the Stem Cells of the Gastrointestinal Epithelium
Potten, C. S., Wilson, J. W., & Booth, C. (1997) · STEM CELLS · doi:10.1002/stem.150082 · Cited by 287
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes
Lin, J. H., & Lu, A. Y. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.535 · Cited by 285
Differential Induction of Prehepatic and Hepatic Metabolism of Verapamil by Rifampin
Fromm, M. F., Busse, D., Kroemer, H. K., & Eichelbaum, M. (1996) · Hepatology · doi:10.1002/hep.510240407 · Cited by 283
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*
Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 282
P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine
Mouly, S., & Paine, M. F. (2003) · Pharmaceutical Research · doi:10.1023/a:1026183200740 · Cited by 276
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*
Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P., & Hebert, M. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90150-8 · Cited by 268
Schuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
Human CYP2B6: expression, inducibility and catalytic activities
Gervot, L., Rochat, B., Gautier, J. C., Bohnenstengel, F., Kroemer, H., de Berardinis, V., Martin, H., Beaune, P., & de Waziers, I. (1999) · Pharmacogenetics · doi:10.1097/00008571-199906000-00004 · Cited by 265
Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L., Bhat, K., Kim, R. B., & Wilkinson, G. R. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00003 · Cited by 261
Guengerich, F. P., Brian, W. R., Iwasaki, M., Sari, M. A., Baeaernhielm, C., & Berntsson, P. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00110a012 · Cited by 260
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
Distribution of Soluble Epoxide Hydrolase and of Cytochrome P450 2C8, 2C9, and 2J2 in Human Tissues
Enayetallah, A. E., French, R. A., Thibodeau, M. S., & Grant, D. F. (2004) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540405200403 · Cited by 255
Drug Interactions with Grapefruit Juice: Extent, Probable Mechanism and Clinical Relevance
Fuhr, U. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00002 · Cited by 252
Strassburg, C. P., Kneip, S., Topp, J., Obermayer-Straub, P., Barut, A., Tukey, R. H., & Manns, M. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002180200 · Cited by 249
Clinical Pharmacokinetics: Concepts and Applications
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-6-500_4 · Cited by 247
Gibbs, M. A., Thummel, K. E., Shen, D. D., & Kunze, K. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15274-9 · Cited by 245
Spiecker, M., Darius, H., Hankeln, T., Soufi, M., Sattler, A. M., Schaefer, J. R., Node, K., Börgel, J., Mügge, A., Lindpaintner, K., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143832.91812.60 · Cited by 240
The Mucosa of the Small Intestine: How Clinically Relevant as an Organ of Drug Metabolism?
Doherty, M. M., & Charman, W. N. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00001 · Cited by 239
Molecular and physical mechanisms of first-pass extraction.
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · PubMed · Cited by 235
In Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance
Soars, M. G., Burchell, B., & Riley, R. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.382 · Cited by 228
The drug efflux–metabolism alliance: biochemical aspects
Benet, L. Z., & Cummins, C. L. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00178-8 · Cited by 226
THE SMALL INTESTINE AS A XENOBIOTIC-METABOLIZING ORGAN
Kaminsky, L. S., & Zhang, Q.-Y. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.12.1520 · Cited by 219
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
Kupferschmidt, H. H. T., Fattinger, K. E., Ha, H. R., Follath, F., & Krahenbuhl, S. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00687.x · Cited by 214
Characterization of epithelial cell shedding from human small intestine
Bullen, T. F., Forrest, S., Campbell, F., Dodson, A. R., Hershman, M. J., Pritchard, D. M., Turner, J. R., Montrose, M. H., & Watson, A. J. M. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700464 · Cited by 214
Gibson, G. G., Plant, N. J., Swales, K. E., Ayrton, A., & El-Sankary, W. (2002) · Xenobiotica · doi:10.1080/00498250110102674 · Cited by 211
Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., & Vyas, K. P. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07382-9 · Cited by 209
Berggren, S., Gall, C., Wollnitz, N., Ekelund, M., Karlbom, U., Hoogstraate, J., Schrenk, D., & Lennernäs, H. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0600687 · Cited by 208
Gorski, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00187-5 · Cited by 205
Fetus-specific expression of a form of cytochrome P-450 in human livers
Komori, M., Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., & Kamataki, T. (1990) · Biochemistry · doi:10.1021/bi00470a024 · Cited by 201
Benet, L. Z., Wu, C.-Y., Hebert, M. F., & Wacher, V. J. (1996) · Journal of Controlled Release · doi:10.1016/0168-3659(95)00147-6 · Cited by 198
Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract
Thörn, M., Finnström, N., Lundgren, S., Rane, A., & Lööf, L. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02389.x · Cited by 196
Yeh, R. F., Gaver, V. E., Patterson, K. B., Rezk, N. L., Baxter-Meheux, F., Blake, M. J., Eron, J. J., Klein, C. E., Rublein, J. C., & Kashuba, A. D. M. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000219774.20174.64 · Cited by 194
Johnson, B. M., Charman, W. N., & Porter, C. J. H. (2002) · AAPS PharmSci · doi:10.1208/ps040440 · Cited by 193
Gene structure ofCYP2C8 and extrahepatic distribution of the human CYP2Cs
Klose, T. S., Blaisdell, J. A., & Goldstein, J. A. (1999) · Journal of Biochemical and Molecular Toxicology · Cited by 189
Pade, V., & Stavchansky, S. (1997) · Pharmaceutical Research · doi:10.1023/a:1012111008617 · Cited by 185
Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine
Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A. K., Neuhaus, P., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202345200 · Cited by 185
In vitro systems for studying intestinal drug absorption
Hillgren, K. M., Kato, A., & Borchardt, R. T. (1995) · Medicinal Research Reviews · doi:10.1002/med.2610150202 · Cited by 182
Benton, R. E., Honig, P. K., Zamani, K., Cantilena, L. R., & Woosley, R. L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90105-8 · Cited by 181
Cytochrome P450 enzymes: Central players in cardiovascular health and disease
Elbekai, R. H., & El-Kadi, A. O. S. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.011 · Cited by 181
Eagling, Profit, & Back (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00052.x · Cited by 179
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
Holtbecker, N., Fromm, M. F., Kroemer, H. K., Ohnhaus, E. E., & Heidemann, H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08415-6 · Cited by 178
Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4505 · Cited by 178
Best and Taylor's Physiological Basis of Medical Practice
Iatridis, P. G. (1985) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1985.03350410153046 · Cited by 176
The Biochemistry of Drug Metabolism – An Introduction: Part 2. Redox Reactions and Their Enzymes
Testa, B., & Krämer, S. D. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790032 · Cited by 171
Lundahl, J., Regårdh, C. G., Edgar, B., & Johnsson, G. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050263 · Cited by 165
The human drug metabolizing cytochromes P450
Wrighton, S. A., VandenBranden, M., & Ring, B. J. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353474 · Cited by 164
Clinical Pharmacokinetics of Fluvastatin
Scripture, C. D., & Pieper, J. A. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00003 · Cited by 163
Galetin, A., & Houston, J. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106013 · Cited by 160
Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes
Hashizume, T., Imaoka, S., Mise, M., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., & Funae, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.298 · Cited by 159
Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues
Windmill, K. (2000) · Toxicological Sciences · doi:10.1093/toxsci/54.1.19 · Cited by 159
Importance of P‐glycoprotein for drug disposition in humans
Fromm, M. F. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.4.x · Cited by 158
Medicinal importance of grapefruit juice and its interaction with various drugs
Kiani, J. G., & Imam, S. Z. (2007) · Nutrition Journal · doi:10.1186/1475-2891-6-33 · Cited by 158
P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans
Drescher, S., Glaeser, H., Mürdter, T., Hitzl, M., Eichelbaum, M., & Fromm, M. F. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.27 · Cited by 158
Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity
Peter Guengerich, F. (1994) · Toxicology Letters · doi:10.1016/0378-4274(94)90156-2 · Cited by 158
Expression of CYP2A genes in human liver and extrahepatic tissues
Koskela, S., Hakkola, J., Hukkanen, J., Pelkonen, O., Sorri, M., Saranen, A., Anttila, S. L., Fernández‐Salguero, P. M., Gonzalez, F. J., & Raunio, H. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00015-5 · Cited by 155
Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.
McKinnon, R. A., Burgess, W. M., Hall, P. M., Roberts‐Thomson, S. J., Gonzalez, F. J., & McManus, M. E. (1995) · Gut · doi:10.1136/gut.36.2.259 · Cited by 155
LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE
Fakhoury, M., Litalien, C., Médard, Y., Cavé, H., Ezzahir, N., Peuchmaur, M. M., & Jacqz-Aigrain, É. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005611 · Cited by 155
Inui, K., Yamamoto, M., & Saito, H. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10961-0 · Cited by 154
Mammalian cytochromes P450—Importance of tissue specificity
Seliškar, M., & Rozman, D. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.09.016 · Cited by 154
Tissue distribution of drug-metabolizing enzymes in humans
Pacifici, G. M., Franchi, M. P., Bencini, C., Repetti, F., Lascio, N. D., & Muraro, G. B. (1988) · Xenobiotica · doi:10.3109/00498258809041723 · Cited by 150
Lasker, J. M., Wester, M. R., Aramsombatdee, E., & Raucy, J. L. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0615 · Cited by 150
Murray, G. I., Barnes, T., Hf, S., Ewen, S. W. B., Melvin, W., & Burke, M. D. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03331.x · Cited by 147
Hepatic stem cells: from inside and outside the liver?
Alison, M. R., Vig, P., Russo, F. P., Bigger, B., Amofah, E., Themis, M., & Forbes, S. J. (2004) · Cell Proliferation · doi:10.1111/j.1365-2184.2004.00297.x · Cited by 146
The presence of a monooxygenase system in human fetal liver microsomes
Yaffe, S. J., Rane, A., Sjöqvist, F., Boréus, L. O., & Orrenius, S. (1970) · Life Sciences · doi:10.1016/0024-3205(70)90038-x · Cited by 145
Differential expression and function of CYP2C isoforms in human intestine and liver
pple, F. L., von Richter, O., Fromm, M. F., Richter, T., Thon, K. P., Wisser, H., Griese, E., Eichelbaum, M. F., & Kivist, K. T. (2003) · Pharmacogenetics · doi:10.1097/00008571-200309000-00005 · Cited by 144
THE TURNOVER OF THE EPITHELIUM OF THE SMALL INTESTINE
Creamer, B. (1967) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a070561 · Cited by 143
Windmill, K., McKinnon, R. A., Zhu, X., et al. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00038-9 · Cited by 142
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang, L., Wring, S. A., Woolley, J. L., Brouwer, K. R., Serabjit‐Singh, C. J., & Polli, J. W. (2001) · PubMed · Cited by 142
The physiological and pharmacological roles of cytochrome P450 isoenzymes
Chang, G. W., & Kam, P. C. A. (1999) · Anaesthesia · doi:10.1046/j.1365-2044.1999.00602.x · Cited by 140
Fontana, R. J., Lown, K. S., Paine, M. F., Fortlage, L., Santella, R. M., Felton, J. S., Knize, M. G., Greenberg, A., & Watkins, P. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70554-8 · Cited by 137
Metabolic characterization of the major human small intestinal cytochrome p450s.
Obach, R. S., Zhang, Q., Dunbar, D. A., & Kaminsky, L. S. (2001) · PubMed · Cited by 136
Zeldin, D. C., Foley, J. F., Goldsworthy, S. M., Cook, M. E., Boyle, J. E., Ma, J., Moomaw, C. R., Tomer, K. B., Steenbergen, C., & Wu, S. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.931 · Cited by 135
Chiba, M., Hensleigh, M., & Lin, J. H. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00100-7 · Cited by 134
Factors affecting the absolute bioavailability of nifedipine.
Rashid, T. J., Martin, U., Clarke, H., Waller, D., Renwick, A., & George, C. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04534.x · Cited by 133
Polymorphism of cytochrome P450 and xenobiotic toxicity
Ingelman‐Sundberg, M. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00492-4 · Cited by 129
Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach
Ito, K., Kusuhara, H., & Sugiyama, Y. (1999) · Pharmaceutical Research · doi:10.1023/a:1018872207437 · Cited by 123
Functional interaction of intestinal CYP3A4 and P‐glycoprotein
Kivistö, K. T., Niemi, M., & Fromm, M. F. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00291.x · Cited by 120
Bork, R. W., Muto, T., Beaune, P. H., Srivastava, P. K., Lloyd, R. S., & Guengerich, F. P. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85029-9 · Cited by 118
In Vitro Methods to Study Intestinal Drug Metabolism
van de Kerkhof, E. G., de Graaf, I., & Groothuis, G. M. M. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109742 · Cited by 114
UDP-glucuronosyltransferases in human intestinal mucosa
Radominska-p, A., Little, J. M., Pandya, J. T., Tephly, T. R., King, C. D., Barone, G. W., & Raufman, J. (1998) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(98)00115-5 · Cited by 113
Involvement of CYP2J2 on the Intestinal First-Pass Metabolism of Antihistamine Drug, Astemizole
Matsumoto, S., Hirama, T., Matsubara, T., Nagata, K., & Yamazoe, Y. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1240 · Cited by 113
YU, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.009 · Cited by 113
Saarikoski, S. T., Rivera, S. P., Hankinson, O., & Husgafvel‐Pursiainen, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.027 · Cited by 112
Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract
McDonnell, W. M., Scheiman, J. M., & Traber, P. G. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91171-y · Cited by 110
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Cummins, C. L., Jacobsen, W., Christians, U., & Benet, L. Z. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058065 · Cited by 108
Lennernäs, H. (1995) · Pharmaceutical Research · doi:10.1023/a:1016220428705 · Cited by 106
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue
Kivistö, K. T., Bookjans, G., Fromm, M. F., Griese, E., Münzel, P., & Kroemer, H. K. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.42615.x · Cited by 106
Identification and Tissue Distribution of the Novel Human Cytochrome P450 2S1 (CYP2S1)
Rylander‐Rudqvist, T., Neve, E. P. A., Ingelman‐Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4390 · Cited by 106
The Biochemistry of Drug Metabolism – An Introduction
Testa, B., & Krämer, S. D. (2006) · Chemistry & Biodiversity · doi:10.1002/cbdv.200690111 · Cited by 104
Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450
Mountfield, R. J., Senepin, S., Schleimer, M., et al. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00586-x · Cited by 103
Novel extrahepatic cytochrome P450s
Karlgren, M., MIURA, S., & Ingelman‐Sundberg, M. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.12.022 · Cited by 101
Characterization of rat small intestinal cytochrome P450 composition and inducibility.
Zhang, Q. Y., Wikoff, J., Dunbar, D. A., & Kaminsky, L. S. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07350-7 · Cited by 101
Chalasani, N., Gorski, J. C., Patel, N. H., Hall, S. D., & Galinsky, R. E. (2001) · Hepatology · doi:10.1053/jhep.2001.29306 · Cited by 98
Reactive intermediates and their toxicological significance
Monks, T. J., & Lau, S. S. (1988) · Toxicology · doi:10.1016/0300-483x(88)90195-3 · Cited by 97
Effects of grapefruit juice and smoking on verapamil concentrations in steady state
Fuhr, U., Müller-Peltzer, H., Kern, R., Lopez-Rojas, P., Jünemann, M., Harder, S., & Staib, H. A. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0436-7 · Cited by 97
EXPRESSION OF CYP3A ISOFORMS AND P‐GLYCOPROTEIN IN HUMAN STOMACH, JEJUNUM AND ILEUM
Canaparo, R., Finnström, N., Serpe, L., Nordmark, A., Muntoni, E., Eandi, M., Rane, A., & Zara, G. P. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04691.x · Cited by 96
Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
Glaeser, H., Drescher, S., Eichelbaum, M. F., & Fromm, M. F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02265.x · Cited by 94
Paine, M. F., Schmiedlin‐Ren, P., & Watkins, P. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14911-2 · Cited by 91
von Richter, O., Greiner, B., Fromm, M. F., FRASER, R., Omari, T. I., Barclay, M. L., Dent, J., Somogyi, A. A., & Eichelbaum, M. F. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117937 · Cited by 91
Cytochromes P-450 in the intestinal mucosa of man
Peters, W. H. M., & Kremers, P. G. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90194-9 · Cited by 90
Madani, S., Paine, M. F., Lewis, L., Thummel, K. E., & Shen, D. D. (1999) · Pharmaceutical Research · doi:10.1023/a:1018989211864 · Cited by 85
Kitada, M., Kamataki, T., Itahashi, K., et al. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90350-9 · Cited by 83
Cytochrome P450 3A expression and activity in the human small intestine
YANG, J., Tucker, G. T., & Rostami‐Hodjegan, A. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.001 · Cited by 80
Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?
Jounaïdi, Y., Hyrailles, V., Gervot, L., & Maurel, P. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0618 · Cited by 80
Yamazaki, H., Niwa, T., Murayama, N., & Emoto, C. (2008) · Current Drug Metabolism · doi:10.2174/138920008783331121 · Cited by 75
Variable expression of CYP and Pgp genes in the human small intestine
Lindell, M., Karlsson, M. O., Lennernäs, H., Påhlman, L., & Lang, M. A. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01154.x · Cited by 74
In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
Hirota, N., Ito, K., Iwatsubo, T., Green, C. E., Tyson, C. A., Shimada, N., Suzuki, H., & Sugiyama, Y. (2001) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.261 · Cited by 73
Hu, M., & Borchardt, R. T. (1990) · Pharmaceutical Research · doi:10.1023/a:1015906409585 · Cited by 72
cDNA Cloning and Expression of a Novel Cytochrome P450 (CYP4F12) from Human Small Intestine
Hashizume, T., Imaoka, S., Hiroi, T., Terauchi, Y., Fujii, T., Miyazaki, H., Kamataki, T., & Funae, Y. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4238 · Cited by 68
Galetin, A., Hinton, L., Burt, H. J., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109805 · Cited by 66
Human gastrointestinal sulfotransferases: identification and distribution☆
Chen, G., Zhang, D., Jing, N., Yin, S., Falany, C. N., & Radominska-Pandya, A. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(02)00073-x · Cited by 61
Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.
Gupta, S., Kim, J., & Gollapudi, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115154 · Cited by 60
REN, X., Mao, X., Si, L., Cao, L., XIONG, H., Qiu, J., Schimmer, A. D., & Li, G. Q. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.03.019 · Cited by 57
Transport Proteins and Intestinal Metabolism
Christians, U. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00002 · Cited by 54
Pharmacokinetics of felodipine in patients with liver disease
Reg�rdh, C. G., Edgar, B., Olsson, R., Kendall, M. J., Collste, P., & Shansky, C. W. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558072 · Cited by 54
Glaeser, H., Drescher, S., van der Kuip, H., Behrens, C., Geick, A., Burk, O., Dent, J., Somogyi, A. A., von Richter, O., Griese, E., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121370 · Cited by 54
Erythromycin enhances the absorption of cyclosporin.
Gupta, S. K., Bakran, A., Johnson, R. W. G., & Rowland, M. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03320.x · Cited by 53
Ageing and duodenal morphometry.
Lipski, P., Bennett, M., Kelly, P., & James, O. F. W. (1992) · Journal of Clinical Pathology · doi:10.1136/jcp.45.5.450 · Cited by 52
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation
Kim, H. J., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40126j · Cited by 750
Furness, J. B., Rivera, L. R., Cho, H.-J., Bravo, D. M., & Callaghan, B. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.180 · Cited by 526
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
Kuepfer, L., Niederalt, C., Wendl, T., Schlender, J., Willmann, S., Lippert, J., Block, M., Eissing, T., & Teutonico, D. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12134 · Cited by 425
Berry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
Metadata
- Authors
- Thelen, K., & Dressman, J. B.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-01
- Volume
- 61
- Issue
- 5
- Pages
- 541-558
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W4210979734
- Cited by
- 338
- References
- 216
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.